한빛사논문
- 조회1,045
건국대학교
Govindarajan Karthivashana,c,1, Palanivel Ganesana,d,1, Shin-Young Parka, Ho-Won Leeb, Dong-Kug Choia,c,*
a Department of Biotechnology, College of Biomedical and Health Science, Konkuk University, Chungju 27478, Republic of Korea
b Department of Neurology, Kyungpook National University School of Medicine and Brain Science & Engineering Institute, Kyungpook National University, Daegu, 41404, Republic of Korea
c Research Institute of Inflammatory Diseases (RID), College of Biomedical and Health Science and BK21plus Glocal Education Program of Nutraceuticals Development, Konkuk University, Chungju 27478, Republic of Korea
d Department of Biomedical Chemistry, Nanotechnology Research Center, and Department of Applied Life Science, College of Biomedical and Health Science, Konkuk University, Chungju 27478, Republic of Korea
*Corresponding author : Dong-Kug Choi
1Equal contributing first author
Abstract
The incidence of Parkinson's disease (PD), the second most common neurodegenerative disorder, has increased exponentially as the global population continues to age. Although the etiological factors contributing to PD remain uncertain, its average incidence rate is reported to be 1% of the global population older than 60 years. PD is primarily characterized by the progressive loss of dopaminergic (DAergic) neurons and/or associated neuronal networks and the subsequent depletion of dopamine (DA) levels in the brain. Thus, DA or levodopa (L-dopa), a precursor of DA, represent cardinal targets for both idiopathic and symptomatic PD therapeutics. While several therapeutic strategies have been investigated over the past decade for their abilities to curb the progression of PD, an effective cure for PD is currently unavailable. Even DA replacement therapy, an effective PD therapeutic strategy that provides an exogenous supply of DA or L-dopa, has been hindered by severe challenges, such as a poor capacity to bypass the blood–brain barrier and inadequate bioavailability. Nevertheless, with recent advances in nanotechnology, several drug delivery systems have been developed to bypass the barriers associated with central nervous system therapeutics. In here, we sought to describe the adapted lipid-based nanodrug delivery systems used in the field of PD therapeutics and their recent advances, with a particular focus placed on DA replacement therapies. This work initially explores the background of PD; offers descriptions of the most recent molecular targets; currently available clinical medications/limitations; an overview of several lipid-based PD nanotherapeutics, functionalized nanoparticles, and technical aspects in brain delivery; and, finally, presents future perspectives to enhance the use of nanotherapeutics in PD treatment.
Keywords : Parkinson’s disease; dopamine/levodopa; blood–brain barrier; nanodrug delivery; lipid-based nanoparticles
논문정보
- Review Paper
- 2019년 12월 (BRIC 등록일 2019-12-31)
- 국내 연구진
댓글 작성 로그인
팝업 닫기관련 링크
연구자 키워드
연구자 ID
관련분야 연구자보기
소속기관 논문보기
관련분야 논문보기
